Article
Use of statin for patients with glioblastoma multiforme
Search Medline for
Authors
-
Jorge Humberto Tapia-Pérez
- Universitätsklinik für Neurochirurgie, Otto-von-Guericke Universität, Magdeburg, Germany
-
Katharina Groehl
- Universitätsklinik für Neurochirurgie, Otto-von-Guericke Universität, Magdeburg, Germany
-
Sonja Gehring
- Klinik für Hämato-onkologie, Otto-von-Guericke Universität, Magdeburg, Germany
-
Thomas Schneider
- Universitätsklinik für Neurochirurgie, Otto-von-Guericke Universität, Magdeburg, Germany
| Published: | June 2, 2015 |
|---|
Outline
Text
Objective: Statins are drugs used for cardiovascular protection and in the last years aspects regarding their anti-tumor effect have been actively studied. Especially one large epidemiological study has suggested the benefit of the long-term use of statin for patients with GBM. Our study analyzes, whether statin use after the diagnosis of GBM is related to progression or whether it impacts the overall survival (OS).
Method: We retrospectively assessed 85 patients with histologicalyl confirmed GBM that underwent radiotherapy (RT) or radiochemotherapy (RCT) after tumor resection. OS and progression-free survival (PFS) were evaluated by Kaplan Meier curves and Cox regression in correlation to statin use during follow-up.
Results: 18 Statin users were compared to 67 non-users. An MRI-proven complete resection was achieved in 9 statin-users and 47 non-users. Statin users were significantly older (median 69.3 and 59.9 years, respectively) and had more co-morbidities than non-users (e.g. diabetes mellitus [DM], hypertension). After adjusting for other variables (age, Karnofsky, resection grade, steroide use, RTA/RTOG, DM) statin-use kept significant for 12-months OS (HR 2.7, 95% CI 1.25-5.82, p=0.01). In a paired analysis controlling for age, sex, and Karnofsky score, statin-use was not more significant (HR= 2.13, 0.87-5.21, p=0.096), while DM remained significant in the models for 12-months OS (HR= 4.79, 95%C CI 1.82-12.59). In both analyses (paired and non-paired), we did not find any association to PFS.
Conclusions: The use of statins after the diagnosis of GBM is not related to tumor progression and the overall survival does not seem to be directly impaired by statin use, while it is impaired by the presence of co-morbidities, such as diabetes mellitus.
